Braveheart Bio (NASDAQ:BRVE) Stock Price Up 7.9% - Should You Buy?

Key Points

• Braveheart Bio shares rose 7.9% to $20.73, although trading volume was 89% below the average session volume.
• Analysts maintain a generally positive outlook, with five Buy ratings and one Hold rating, a “Moderate Buy” consensus, and an average price target of $45.25.
• The company reported a significant quarterly EPS miss of $2.51 versus the expected $0.25 loss, but insiders bought 8.75 million shares worth approximately $157.5 million over the past 90 days.

Shares of Braveheart Bio, Inc. (NASDAQ:BRVE - Get Free Report) traded up 7.9% on Tuesday. The stock traded as high as $20.32 and last traded at $20.73. 52,851 shares traded hands during trading, a decline of 89% from the average session volume of 459,622 shares. The stock had previously closed at $19.21.

Analysts Set New Price Targets

BRVE has been the subject of several recent analyst reports. Zacks Research raised Braveheart Bio to a "hold" rating in a research note on Tuesday, September 1st. Wall Street Zen upgraded shares of Braveheart Bio to a "hold" rating in a report on Saturday, August 15th. Jefferies Financial Group assumed coverage on shares of Braveheart Bio in a research note on Monday, August 31st. They set a "buy" rating and a $48.00 price target on the stock. TD Cowen started coverage on Braveheart Bio in a research note on Monday, August 31st. They set a "buy" rating for the company. Finally, The Goldman Sachs Group assumed coverage on shares of Braveheart Bio in a report on Monday, August 31st. They set a "buy" rating and a $48.00 price objective on the stock. Five equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, Braveheart Bio presently has an average rating of "Moderate Buy" and a consensus target price of $45.25.

Braveheart Bio Trading Up 7.0%

The firm has a fifty day moving average price of $24.50. The stock has a market capitalization of $1.85 billion and a price-to-earnings ratio of -8.20.

Braveheart Bio (NASDAQ:BRVE - Get Free Report) last announced its quarterly earnings data on Tuesday, September 8th. The company reported ($2.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($2.26). Analysts predict that Braveheart Bio, Inc. will post -1.48 EPS for the current year.

Insider Activity at Braveheart Bio

In related news, Director Erez Chimovits bought 1,940,000 shares of the stock in a transaction that occurred on Friday, August 7th. The shares were acquired at an average price of $18.00 per share, with a total value of $34,920,000.00. Following the completion of the transaction, the director owned 11,901,826 shares in the company, valued at $214,232,868. The trade was a 19.47% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Christopher Viehbacher acquired 83,333 shares of the stock in a transaction on Friday, August 7th. The shares were purchased at an average price of $18.00 per share, for a total transaction of $1,499,994.00. Following the transaction, the director directly owned 609,519 shares in the company, valued at approximately $10,971,342. This trade represents a 15.84% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired 8,751,942 shares of company stock valued at $157,534,956 over the last ninety days.

Braveheart Bio Company Profile

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.